Marianne Spengler Megan Wheelden Heath B Mackley Joseph J Drabick
10.1200/PO.20.00486
JCO Precis Oncol
2021 Apr 19;5:PO.20.00486.
CC BY-NC-ND
https://pubmed.ncbi.nlm.nih.gov/34036225/
Esthesioneuroblastoma, Olfactory / drug therapy Indazoles / therapeutic use Nasal Cavity Neoplasm Recurrence, Local / drug therapy Nose Neoplasms / drug therapy Pyrimidines / therapeutic use Sulfonamides / therapeutic use
Esthesioneuroblastoma, Olfactory / drug therapy Indazoles / therapeutic use Nasal Cavity Neoplasm Recurrence, Local / drug therapy Nose Neoplasms / drug therapy Pyrimidines / therapeutic use Sulfonamides / therapeutic use Case Reports Aged Esthesioneuroblastoma, Olfactory / genetics Esthesioneuroblastoma, Olfactory / secondary Female Fumarate Hydratase / genetics Humans Mutation Nose Neoplasms / genetics Nose Neoplasms / pathology Remission Induction Retreatment Time Factors Indazoles Pyrimidines Sulfonamides pazopanib Fumarate Hydratase
PMC8140788
34036225
Durable Major Response With Pazopanib in Recurrent, Heavily Pretreated Metastatic Esthesioneuroblastoma Harboring a Fumarate Hydratase Mutation
2021